2016
DOI: 10.1182/blood.v128.22.4414.4414
|View full text |Cite
|
Sign up to set email alerts
|

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Abstract: Background: Treatment of multiple myeloma has evolved considerably in the past few years with availability of several news drugs as well as increasing use of multidrug combinations. These changes have no doubt led to the improved survival seen among patients with MM. We have previously shown that outcomes of patients intolerant or refractory to one of the IMiDs and bortezomib had a poor outcome. Since that time, other drugs of the same class as well as new classes of drugs have been introduced for the treatmen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
65
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(68 citation statements)
references
References 0 publications
3
65
0
Order By: Relevance
“…However, a cure for MM is still elusive. Patients who were exposed to at least 3 prior lines of therapy, were refractory to a PI and an IMiD, and were exposed to an alkylating agent, had an OS of only 13 months and progression‐free survival (PFS) of 5 months in a recent multicenter study …”
Section: Introductionmentioning
confidence: 99%
“…However, a cure for MM is still elusive. Patients who were exposed to at least 3 prior lines of therapy, were refractory to a PI and an IMiD, and were exposed to an alkylating agent, had an OS of only 13 months and progression‐free survival (PFS) of 5 months in a recent multicenter study …”
Section: Introductionmentioning
confidence: 99%
“…Unfortunately, for patients with relapsed and/or refractory disease (RRMM), responses are generally limited and short‐lived and their prognosis remains unfavourable. Median overall survival (OS) in patients who are double refractory to a PI and an IMiD is 9–13 months (Kumar et al , , ). These patients represent a major clinical challenge as data on optimal treatment regimens in this group are limited and trials of new drugs are often difficult to compare.…”
mentioning
confidence: 99%
“…Though remarkable progress has been made in the field of multiple myeloma (MM), with proteasome inhibitors (PIs), immunomodulators (IMiDs) and monoclonal antibodies, the disease is still currently incurable. Outcomes are dismal when patients become refractory to bortezomib, lenalidomide, pomalidomide and daratumumab (quadri‐refractory) (Kumar et al , ; Gandhi et al , ).…”
Section: Patient Characteristicsmentioning
confidence: 99%